Current Colorectal Cancer Reports

, Volume 9, Issue 3, pp 286–291 | Cite as

The Role of Adjuvant Therapy in the Elderly

Adjuvant Therapy for Colon Cancers (AB Benson III and A de Gramont, Section Editors)
  • 108 Downloads

Abstract

Colorectal cancer is the third commonest cancer and second commonest cancer killer in the USA. With a median age at diagnosis of 72 years, it largely affects the elderly population. However, there is a lack of objective data with which to answer clinically relevant questions regarding adjuvant therapy in the geriatric patient population because mainly younger patients are enrolled in clinical trials. Elderly patients are undertreated in the adjuvant setting owing to multiple factors, including physician decision and patient preference. Older patients have different tumor biology, physiologic factors, and social situations to consider in comparison with younger patients. Thus, geriatric patients require more thorough assessment of their functional status and existing medical conditions as they are at risk of increased toxicities from chemotherapy and their ongoing treatment requires vigilance. Elderly patients do benefit from adjuvant chemotherapy, although subgroup analyses show that many do not derive incremental benefit from the addition of oxaliplatin to 5-fluorouracil therapy.

Keywords

Adjuvant chemotherapy Colon cancer Elderly 5-Fluorouracil Oxaliplatin 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Christina Wu is supported by grants from the National Comprehensive Cancer Network and the American Cancer Society.

Richard M. Goldberg is supported by a grant from Sanofi, has received a consulting fee/honorarium from Sanofi and Bayer, has received support for travel to meetings from Sanofi and Bayer, has received compensation for participating in review activities from Lilly and Pfizer, and has received payment for lectures, including service on speakers bureaus, from Fresenius Kabi, and Yakult.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    American Cancer Society. Cancer facts & figures 2012. Atlanta: American Cancer Society; 2012.Google Scholar
  2. 2.
    Pallis AG, Fortpied C, Wedding U, et al. EORTC Elderly Task Force experts’ opinion for the treatment of colon cancer in older patients. Cancer Treat Rev. 2010;36:83–90.PubMedCrossRefGoogle Scholar
  3. 3.
    National Center for Health Statistics: Health, United States. 2009. http://seer.cancer.gov/csr/1975_2009_pops09/results_single/sect_01_table.11_2pgs.pdf. Accessed 3 Apr 2013.
  4. 4.
    Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–51.PubMedCrossRefGoogle Scholar
  5. 5.
    Abraham A, Haberman EB, Rothenberger DA, et al. Adjuvant chemotherapy for stage III colon cancer in the oldest old. Cancer. 2013;119:395–403.PubMedCrossRefGoogle Scholar
  6. 6.
    Charlson ME, Pompei P, Alex KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRefGoogle Scholar
  7. 7.
    Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25:1824–31.PubMedCrossRefGoogle Scholar
  8. 8.
    Goel A, Nagasaka T, Arnold CN, et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 2007;132:127–38.PubMedCrossRefGoogle Scholar
  9. 9.
    Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One. 2008;3:e3698.PubMedCrossRefGoogle Scholar
  10. 10.
    •• Sargent DJ, Marsoni S, Monges G. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;38:3219–26. This article reports the improved outcome for patients with tumors that have defective mismatch repair, and the lack of benefit with adjuvant 5-FU chemotherapy with stage II colon cancer. MSI or defective mismatch repair is a marker used in determining whether patients will benefit from adjuvant 5-FU.CrossRefGoogle Scholar
  11. 11.
    Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011;103:863–75.PubMedCrossRefGoogle Scholar
  12. 12.
    Kahn KL, Adams JL, Chrischilles EA, et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA. 2010;303:1037–45.PubMedCrossRefGoogle Scholar
  13. 13.
    • Sanoff HK, Carpenter WR, Sturmer T, et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after 75 years. J Clin Oncol. 2012;30:2624–34. This is a pooled analysis of four databases examining whether elderly patients benefit from an oxaliplatin-containing chemoregimen. This supports the subgroup analysis from MOSAIC and C-07 that elderly patients do not benefit from the addition of oxaliplatin to 5-FU chemotherapy.PubMedCrossRefGoogle Scholar
  14. 14.
    Petrioli FG, Lorenzini L, Mancin S, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology. 1994;106:899–906.PubMedGoogle Scholar
  15. 15.
    Marsoni S. Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. Semin Oncol. 2001;28(1 Suppl 1):14–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected cancer in elderly patients. N Engl J Med. 2001;345:1091–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Sanoff HK, Carpenter WR, Martin CF, et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst. 2012;104:211–27.PubMedCrossRefGoogle Scholar
  18. 18.
    Goldberg RM, Tabah‐Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24:4085–91.Google Scholar
  19. 19.
    Jackson McCleary NA, Meyerhardt J, Green E, et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol. 2009;27(15S):4010.Google Scholar
  20. 20.
    •• Tournigand C, Andre T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol. 2012;30:3353–60. This provides a subgroup analyses of the MOSAIC trial, showing that patients with stage II cancer and elderly patients do not benefit from the addition of oxaliplatin to infusional 5-FU chemotherapy.PubMedCrossRefGoogle Scholar
  21. 21.
    •• Yothers G, O’Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;20:3768–74. This provides a subgroup analyses from C-07, in which elderly patients are analyzed and show they do not benefit from the addition of oxaliplatin.CrossRefGoogle Scholar
  22. 22.
    •• Haller DG, Tabernero J, Maroun J, et al. Capectiabine plus oxaliplatin compared with fluororuracil and folinic acid as adjuvant therapy for stage II colon cancer. J Clin Oncol. 2011;29:1465–71. This is a phase III randomized study that shows elderly patients (older than 65 years) benefit from capecitabine and oxaliplatin over bolus 5-FU.PubMedCrossRefGoogle Scholar
  23. 23.
    Haller DG, Cassidy J, Tabernero J, et al. Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): no impact of age on disease-free survival. Gastrointestinal Cancers Symposium, Orlando, January 22–24, 2010 (abstract 284).Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of Medical Oncology, Arthur G. James Comprehensive Cancer CenterThe Ohio State UniversityColumbusUSA
  2. 2.ColumbusUSA

Personalised recommendations